SOFAR acquired by FINE FOODS & PHARMACEUTICALS
Context
The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities. The strategic rationale for this transaction centers on a "technology-integration" play, merging the target's industry-leading expertise in liquid and semi-solid pharmaceuticals with the group’s established global leadership in the CSDMO sector. This fusion effectively creates a specialized powerhouse in the contract manufacturing arena, providing the organization with the technical operational depth required to address the increasing demand for diverse dosage forms. This operation allows the group to execute a definitive structural expansion of its service portfolio, specifically targeting the pharmaceutical and nutraceutical end-markets. By incorporating the target's innovative production facility, the organization can now provide a more robust and integrated solution set for strategic partners looking for comprehensive development support.
SOFAR, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , a level than the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
SOFAR S.p.A. operates as a premier technology organization dedicated to the engineering and distribution of specialized pharmaceutical and nutraceutical solutions. The entity’s business model is centered on a proprietary framework of manufacturing capabilities for liquid and semi-solid dosage forms, providing critical production infrastructure for the microelectronic-precision pharmaceutical industry. Its value proposition is anchored in technical operational depth, offering specialized services for the development of high-quality formulations across diverse therapeutic areas. Strategically, the firm focuses on maintaining industrialized quality standards and operational excellence within its specialized production facilities. By maintaining a specialized focus on technical reliability and complex manufacturing processes, the organization ensures a vital role in the structural advancement of the healthcare supply chain. The entity prioritizes industrialized efficiency and standardized production protocols to facilitate the structural advancement of therapeutic delivery systems.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Generics / Labs |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | UCB | NEURONA THERAPEUTICS | UNITED STATES | R&D Biotech |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Implants & Prosthetics |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
| 04/2026 | ASTORG | THERMO FISHER MICROBIOLOGY | UNITED STATES | Diagnostic Equipment |
| 04/2026 | HALMA | SURGISTAR | UNITED STATES | Medical Devices |
| 04/2026 | VITREX MEDICAL GROUP | HERNIAMESH | ITALY | Implants & Prosthetics |
| 04/2026 | DEVYSER DIAGNOSTICS | CYBERGENE | SWEDEN | Diagnostic Equipment |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Diagnostic Equipment |
REFERENCES
Valuation range: EV 10M - 30M EUR
Revenue range: 25M - 50M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SOFAR by FINE FOODS & PHARMACEUTICALS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.